- Home
- CNTB vs VRCA Comparison
CNTB vs VRCA Comparison
Compare CNTB & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | VRCA |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 137.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNTB | VRCA |
|---|---|---|
| Price | $1.97 | $5.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $8.67 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 302.6K | 30.7K |
| Earning Date | 08-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $64,000.00 | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $1.23 | $0.52 |
| 52 Week High | $3.82 | $9.82 |
Technical Indicators
Market Signals| Indicator | CNTB | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 42.43 |
| Support Level | $1.46 | $5.32 |
| Resistance Level | $2.05 | $6.48 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 11.71 | 3.33 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.